Neil Q. McDonald
Affiliations: | The Francis Crick Institute, London, England, United Kingdom |
Google:
"Neil McDonald"Parents
Sign in to add mentor| Tom Blundell | grad student | Birkbeck College (Computational Biology Tree) |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Yan W, Lakkaniga NR, Carlomagno F, et al. (2020) Correction to Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of Medicinal Chemistry |
| Grey W, Chauhan R, Piganeau M, et al. (2020) Activation of the receptor tyrosine kinase, RET, improves long-term hematopoietic stem cell outgrowth and potency. Blood |
| Moccia M, Frett B, Zhang L, et al. (2020) Bioisosteric discovery of NPA101.3, a second generation RET/VEGFR2 inhibitor optimized for single-agent polypharmacology. Journal of Medicinal Chemistry |
| Jones M, Beuron F, Borg A, et al. (2020) Cryo-EM structures of the XPF-ERCC1 endonuclease reveal how DNA-junction engagement disrupts an auto-inhibited conformation. Nature Communications. 11: 1120 |
| Diring J, Mouilleron S, McDonald NQ, et al. (2019) RPEL-family rhoGAPs link Rac/Cdc42 GTP loading to G-actin availability. Nature Cell Biology |
| Elbediwy A, Zhang Y, Cobbaut M, et al. (2019) The Rho-family GEF FARP2 is activated by aPKCι to control polarity and tight junction formation. Journal of Cell Science |
| Grey W, Chauhan R, Garcia-Albornoz M, et al. (2019) Activation of the Receptor Tyrosine Kinase (RET) By GDNF/GFRα1 Improves Cord Blood-Derived HSC in Vitro expansion and In Vivo engraftment Blood. 134: 1924-1924 |
| Yan W, Lakkaniga NR, Carlomangno F, et al. (2018) Insights into Current Tropomyosin Receptor Kinase (TRK) Inhibitors: Development and Clinical Application. Journal of Medicinal Chemistry |
| Nakaoku T, Kohno T, Araki M, et al. (2018) A secondary RET mutation in the activation loop conferring resistance to vandetanib. Nature Communications. 9: 625 |
| Nakaoku T, Kohno T, Araki M, et al. (2018) Abstract 918: A secondary RET mutation allosterically conferring resistance to vandetanib Cancer Research. 78: 918-918 |